## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

	· · · · · · · · · · · · · · · · · · ·
1	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic
2	SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative
3	design study
4	
5	Authors: Hannah Chung MPH <sup>1</sup> , Siyi He MSc <sup>1</sup> , Sharifa Nasreen PhD <sup>1</sup> , Maria E. Sundaram
6	PhD <sup>1,2</sup> , Sarah A. Buchan PhD <sup>1,2,3,4</sup> , Sarah E. Wilson MD MSc <sup>1,2,3,4</sup> , Branson Chen MSc <sup>1</sup> ,
7	Andrew Calzavara MSc <sup>1</sup> , Deshayne B. Fell PhD <sup>1,5,6</sup> , Peter C. Austin PhD <sup>1,7</sup> , Kumanan Wilson
8	MD MSc <sup>8</sup> , Kevin L. Schwartz MD MSc <sup>1,2,3</sup> , Kevin A. Brown PhD <sup>1,2,3</sup> , Jonathan B. Gubbay MD
9	MSc <sup>3</sup> , Nicole E. Basta PhD <sup>9</sup> , Salaheddin M. Mahmud MD PhD <sup>10</sup> , Christiaan H. Righolt PhD <sup>10</sup> ,
10	Lawrence W. Svenson PhD <sup>11,12,13,14</sup> , Shannon E. MacDonald PhD <sup>13,15</sup> , Naveed Z. Janjua
11	DrPH <sup>16,17</sup> , Mina Tadrous PharmD PhD <sup>1,18</sup> , and Jeffrey C. Kwong MD MSc <sup>1,2,3,4,19,20</sup> on behalf of
12	the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN)
13	Investigators
14	
15	Affiliations:
16	<sup>1</sup> ICES, Toronto, ON
17	<sup>2</sup> Dalla Lana School of Public Health, University of Toronto, Toronto, ON
18	<sup>3</sup> Public Health Ontario, ON
19	<sup>4</sup> Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
20	<sup>5</sup> School of Epidemiology and Public Health, University of Ottawa, ON
21	<sup>6</sup> Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON

<sup>7</sup> Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

- <sup>8</sup> Department of Medicine, University of Ottawa, Ottawa and Bruyere Hospital Research
- 24 Institutes, Ottawa, ON
- <sup>9</sup> Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and
- 26 Global Health, McGill University, Montreal, QC
- <sup>10</sup> Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University
- 28 of Manitoba, Winnipeg, MB
- <sup>11</sup> Analytics and Performance Reporting Branch, Alberta Health, Edmonton, AB
- <sup>12</sup> Division of Preventive Medicine, Faculty of Medicine and Dentistry, University of Alberta,
- 31 Edmonton, AB
- <sup>13</sup> School of Public Health, University of Alberta, Edmonton, AB
- <sup>14</sup> Department of Community Health Sciences, Cumming School of Medicine, University of
- 34 Calgary, Calgary, AB
- <sup>15</sup> Faculty of Nursing, University of Alberta, Edmonton, AB
- <sup>16</sup> British Columbia Centre for Disease Control, Vancouver, BC
- <sup>17</sup> School of Population and Public Health, University of British Columbia, Vancouver, BC
- 38 <sup>18</sup> Women's College Hospital, Toronto, ON
- <sup>19</sup> Department of Family and Community Medicine, University of Toronto, Toronto, ON
- 40 <sup>20</sup> University Health Network, Toronto, ON
- 41

# 42 Corresponding author:

- 43 Jeff Kwong
- 44 Senior Scientist, ICES
- 45 G1 06, 2075 Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

- 46 jeff.kwong@utoronto.ca
- 47 Phone: (416) 480-4055 x1-7665
- 48 Fax: (416) 480-6048
- 49
- 50 Abstract word count: 299
- 51 Manuscript word count: 3896
- 52 Tables/Figures: 6
- 53 References: 43

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

#### 54 **ABSTRACT:**

- 55 **Objectives:** To estimate the effectiveness of mRNA COVID-19 vaccines against symptomatic
- 56 infection and severe outcomes.
- 57 **Design:** We applied a test-negative design study to linked laboratory, vaccination, and health
- administrative databases, and used multivariable logistic regression adjusting for demographic
- and clinical characteristics associated with SARS-CoV-2 and vaccine receipt to estimate vaccine
- 60 effectiveness (VE) against symptomatic infection and severe outcomes.
- 61 Setting: Ontario, Canada between 14 December 2020 and 19 April 2021.
- 62 **Participants:** Community-dwelling adults aged  $\geq 16$  years who had COVID-19 symptoms and
- 63 were tested for SARS-CoV-2.
- 64 Interventions: Pfizer-BioNTech's BNT162b2 or Moderna's mRNA-1273 vaccine.
- 65 Main outcome measures: Laboratory-confirmed SARS-CoV-2 by RT-PCR;
- 66 hospitalization/death associated with SARS-CoV-2 infection.
- 67 Results: Among 324,033 symptomatic individuals, 53,270 (16.4%) were positive for SARS-
- 68 CoV-2 and 21,272 (6.6%) received  $\geq 1$  vaccine dose. Among test-positive cases, 2,479 (4.7%)
- had a severe outcome. VE against symptomatic infection  $\geq 14$  days after receiving only 1 dose
- 70 was 60% (95%CI, 57 to 64%), increasing from 48% (95%CI, 41 to 54%) at 14–20 days after the
- first dose to 71% (95% CI, 63 to 78%) at 35–41 days. VE  $\geq$ 7 days after 2 doses was 91%
- 72 (95% CI, 89 to 93%). Against severe outcomes, VE  $\geq$ 14 days after 1 dose was 70% (95% CI, 60
- 73 to 77%), increasing from 62% (95%CI, 44 to 75%) at 14–20 days to 91% (95%CI, 73 to 97%) at
- $\geq$  35 days, whereas VE  $\geq$  7 days after 2 doses was 98% (95%CI, 88 to 100%). For adults aged  $\geq$  70
- years, VE estimates were lower for intervals shortly after receiving 1 dose, but were comparable

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

- to younger adults for all intervals after 28 days. After 2 doses, we observed high VE against
- 77 E484K-positive variants.
- 78 **Conclusions:** Two doses of mRNA COVID-19 vaccines are highly effective against
- 79 symptomatic infection and severe outcomes. Single-dose effectiveness is lower, particularly for
- 80 older adults shortly after the first dose.

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

### 81 INTRODUCTION

- 82 Understanding how clinical trial efficacy estimates of COVID-19 vaccines translate into real-
- 83 world effectiveness estimates is crucial, given differences in populations, dosing intervals, and
- 84 emerging variants.[1] Due to COVID-19 vaccine supply constraints, Canada's National Advisory
- 85 Committee on Immunization (NACI) recommended extending the interval between doses to a
- 86 maximum of 16 weeks.[2] With vaccine supply constraints globally, determining the
- 87 effectiveness of these vaccines following a single dose vs. two doses is important for informing
- 88 policy for many countries.[1]
- 89 We applied the test-negative design to linked, population-based health databases in
- 90 Ontario, Canada (population 15 million) to evaluate vaccine effectiveness (VE) against
- 91 symptomatic SARS-CoV-2 infection and severe outcomes (i.e., hospitalization or death
- 92 associated with SARS-CoV-2 infection) for two mRNA vaccines (Pfizer-BioNTech's
- 93 BNT162b2 and Moderna's mRNA-1273).

94

#### 95 METHODS

#### 96 Study population, setting, and design

We conducted a test-negative design study among community-dwelling Ontarians who had
symptoms consistent with COVID-19. The test-negative design is comparable to a nested casecontrol design, with symptomatic individuals who are tested for the presence of a pathogen of
interest serving as the nesting cohort.[1,3,4] All Ontarians aged ≥16 years, eligible for provincial
health insurance, not living in long-term care, and who were tested for SARS-CoV-2 between 14
December 2020 and 19 April 2021 were eligible for inclusion. We excluded individuals who
tested positive for SARS-CoV-2 prior to 14 December 2020 and recipients of the ChAdOx1

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

- vaccine. We restricted the analysis to individuals who had at least one relevant COVID-19
- symptom (based on self-report or observation [e.g., measured temperature]) at the time of
- testing, which was collected on the SARS-CoV-2 test requisition (see Supplementary
- 107 Methods). Although these individuals and other members of the general public contributed in
- 108 important ways to this research, it was not feasible to involve study subjects or the public in the
- 109 design, conduct, reporting, or dissemination plans of our research.
- 110

#### 111 Data sources and definitions

112 We linked data from provincial SARS-CoV-2 laboratory testing, COVID-19 vaccination, and

113 health administrative datasets using unique encoded identifiers and analyzed them at ICES

114 (formerly the Institute for Clinical Evaluative Sciences).

115

116 *Outcomes* 

117 Our first primary outcome was symptomatic SARS-CoV-2 infection, ascertained by real-time

118 reverse transcription polymerase chain reaction (RT-PCR) tests on respiratory specimens,

including nasopharyngeal (most common), nasal, throat, saliva, and turbinate.[5] Using data

120 from the Ontario Laboratories Information System (OLIS), which captured 91.8% (n=258,207)

of all provincially reported cases of laboratory-confirmed COVID-19 (n=281,261) during the

study period, test-positive individuals were treated as cases and test-negative individuals were

treated as controls. Since symptom onset dates were inconsistently reported in OLIS, we used the

- specimen collection date as the index date. For cases with multiple positive tests, we used the
- date of their first positive test. For controls with multiple negative tests, we used the date of a
- 126 randomly selected negative test as the index date.

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

127

128	We obtained information on variants and mutations from the Public Health Case and Contact
129	Management system (CCM), which contains information on the clinical course of cases and the
130	results of screening tests for N501Y and E484K mutations and whole genome sequencing results
131	that identify specific variant of concern (VOC) lineages (Alpha [B.1.1.7], Beta [B.1.351],
132	Gamma [P.1]). All RT-PCR-positive specimens with cycle threshold values $\leq$ 35 were tested for
133	the N501Y mutation (starting 3 February 2021) and the E484K mutation (starting 22 March
134	2021).[6] We considered samples with positive N501Y and negative E484K mutations as Alpha,
135	and samples with positive N501Y and E484K mutations as Beta or Gamma. We combined the
136	latter two lineages for our analysis because there were very small numbers of cases identified
137	using whole genome sequencing.
138	
139	Our second primary outcome was severe disease associated with symptomatic SARS-CoV-2
140	infection, defined as either hospitalization or death with a recent positive test, using the earliest
141	of the specimen collection date or the hospitalization or death date as the index date. We
142	identified these outcomes using CCM (for both hospitalizations and deaths), the Canadian
143	Institute for Health Information's Discharge Abstract Database (DAD; for hospitalizations), and
144	the Ontario Registered Persons Database (RPDB; for deaths). For hospitalizations identified
145	using DAD, a positive test must have occurred within 14 days prior to or 3 days after admission.
146	For deaths identified using RPDB, a positive test must have occurred within 30 days prior to
147	death or within 7 days post-mortem. We used the same control group as the first primary
148	outcome analysis (i.e., symptomatic individuals who tested negative for SARS-CoV-2).
149	

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

## 150 COVID-19 vaccination

BNT162b2 became available in Ontario on 14 December 2020, and mRNA-1273 on 28 151 December 2020.[7] The initial vaccination phase prioritized high-risk populations such as older 152 adults living in congregate settings, healthcare workers (including non-patient-facing staff 153 working in healthcare institutions), adults living in Indigenous communities, and adults aged  $\geq 80$ 154 years.[7] Ontario had initially followed the manufacturers' recommended dosing schedules (i.e., 155 a 21-day interval for BNT162b2 and a 28-day interval for mRNA-1273), but due to disruptions 156 in vaccine supply in late January 2021, extended the interval to 35-42 days for everyone except 157 158 older adults living in congregate settings and Indigenous individuals. In early March, Ontario adopted NACI's recommendation to delay administration of the second dose by up to 16 weeks 159 for most individuals.[8,9] Eligibility expanded over time, taking into account both age (i.e., 160 graduated expansion by decreasing age) and other high-risk populations, such as individuals with 161 certain health conditions and their caregivers, certain essential frontline workers, and those aged 162 ≥18 years living or working in high-COVID-19-incidence communities (i.e., those 163 disproportionately affected by COVID-19 and where transmission was still high). Adherence to 164 these eligibility criteria varied across regions. As of 19 April 2021, 28% of Ontario adults had 165 received at least one dose of a COVID-19 vaccine.[10] Comprehensive documentation of all 166 COVID-19 vaccination events in Ontario, including product, date of administration, and dose 167 168 number, is recorded in real-time into COVaxON, a centralized COVID-19 vaccine information 169 system. We used the COVaxON file containing events up to 25 April 2021 for these analyses, 170 which likely had records of all vaccinations delivered by 19 April 2021.

171

172 Covariates

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

173	We obtained age, sex, and postal code of residence as of 14 December 2020 from RPDB. We
174	obtained the number of RT-PCR tests for each subject during the 3 months prior to 14 December
175	2020 from OLIS to use as a proxy for highly tested individuals at increased risk of exposure to
176	SARS-CoV-2 infection (e.g., healthcare workers and caregivers of long-term care residents, who
177	must also undergo serial SARS-CoV-2 testing). We grouped testing dates into 2-week periods to
178	capture temporal changes in viral activity and regional vaccine roll-out. We determined the
179	presence of comorbidities that increase the risk of severe COVID-19,[11] identified from various
180	databases using validated algorithms and commonly accepted diagnostic codes, which have been
181	described elsewhere.[12] We ascertained receipt of influenza vaccination during the 2019/2020
182	and/or 2020/2021 influenza season (a proxy for health behaviours) using physician and
183	pharmacist billing claims in the Ontario Health Insurance Plan and Ontario Drug Benefit
184	databases, respectively. We determined the public health unit of residence using the postal code
185	and Statistics Canada Postal Code Conversion File Plus (version 7B) and grouped them into
186	larger regions. We obtained information at the ecologic level of dissemination area (DA) on four
187	important social determinants of health (median household income, proportion of the working
188	population employed as non-health essential workers [i.e., those unable to work from home],
189	average number of persons per dwelling, and proportion of the population who self-identify as a
190	visible minority) from 2016 Census data.[13] <sup>13</sup> DAs generally contain 400-700 individuals.
191	Details related to these covariates are available in <b>eTable 1</b> .
192	

193 Statistical analysis

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

194	We conducted descriptive analyses and calculated standardized differences to compare
195	characteristics between test-positive cases and test-negative controls, and between vaccinated
196	and unvaccinated individuals.
197	
198	We used multivariable logistic regression models to estimate the odds ratio (OR) comparing the
199	odds of vaccination between test-positive cases and test-negative controls (where unvaccinated
200	individuals served as the reference group). We estimated unadjusted and adjusted odds ratios
201	accounting for all covariates listed above. These covariates were selected a priori based on their
202	known associations with SARS-CoV-2 infection or severity and COVID-19 vaccine
203	receipt,[2,11,14] and were assessed as potential confounders (eTable 2).[15] VE was calculated
204	using the following formula: $VE = (1-OR) \times 100\%$ . Individuals without information on
205	exposures, outcomes, or covariates in ICES' data holdings were assumed not to have the
206	exposure, outcome, or covariate, and were categorized as such within the analyses.
207	
208	For the primary analysis, we estimated overall VE (for both mRNA vaccines combined) for
209	those who received only 1 dose by their index date and those who received 2 doses by their index
210	date. We considered index dates within varying intervals after vaccination.
211	
212	We also estimated VE $\geq$ 14 days after the first dose (among those who only received 1 dose) and
213	$\geq$ 7 days after the second dose,[16] stratified by vaccine product (BNT162b2 or mRNA-1273),
214	age group (16–39, 40–69, and $\geq$ 70 years), sex, presence of any comorbidity, epidemic wave

215 (index dates 14 December 2020–7 February 2021, representing wave 2 in Ontario; 8 February

216 2021–21 March 2021, representing the period between wave 2 and wave 3; and 22 March 2021–

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

217	19 April 2021, representing wave 3), and variant (earlier variant vs. Alpha vs. Beta or Gamma).
218	We also estimated VE by varying intervals after vaccination stratified by age group.
219	
220	We repeated these analyses for severe outcomes, with adjustments to the intervals after
221	vaccination due to reduced sample sizes. For example, we evaluated VE for the entire period
222	(i.e., $\geq 0$ days) after receipt of the second dose.
223	
224	Finally, as a sensitivity analysis, we determined VE against symptomatic infection and severe
225	outcomes by varying intervals among only individuals who were vaccinated (treating individuals
226	vaccinated 0-13 days before testing as the reference group) to assess whether systematic
227	differences between vaccinated and unvaccinated individuals in the main analyses were
228	adequately controlled for.[17]
229	
230	All analyses were conducted using SAS Version 9.4 (SAS Institute Inc., Cary, NC). All tests
231	were two-sided and used $p < 0.05$ as the level of statistical significance.
232	
233	RESULTS
234	From 14 December 2020 – 19 April 2021, 2,171,449 unique individuals were tested for SARS-
235	CoV-2. After excluding individuals who had SARS-CoV-2 infection prior to the study period
236	and individuals who had received ChAdOx1 vaccine, 60.5% of those remaining did not have
237	symptoms consistent with COVID-19 or had no symptom information recorded in OLIS, 24.4%
238	were recorded as asymptomatic, and 15.1% had symptoms consistent with COVID-19 recorded

at the time of testing (Figure 1). Grouped together, individuals with COVID-19-like symptoms

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

and those deemed asymptomatic had similar characteristics as the remaining individuals, except
for COVID-19 vaccine uptake, public health unit region, and number of previous SARS-CoV-2
tests (eTable 3).

243

Of the 324,033 symptomatic tested individuals, 53,270 (16.4%) tested positive for SARS-CoV-2, 244 42,567 (79.9%) had variant testing information available, 21,272 (6.6%) had received  $\geq 1$  dose of 245 mRNA vaccine, and 4,894 (1.5%) had received 2 doses (Table 1). Among test-positive cases, 246 247 2,479 (4.7%) had a severe outcome, of which 2,035 were hospitalized and 444 had died. Most hospitalized cases tested positive prior to or on admission date (1,728 [84.9%]) and nearly all 248 tested positive before death. Test-positive cases were more likely to be male; more likely to 249 reside in Peel Region or Toronto; more likely to have had zero SARS-CoV-2 tests during the 3 250 months prior to the vaccination program; less likely to have received an influenza vaccine; and 251 more likely to reside in neighbourhoods with lower income, more persons per dwelling, and 252 greater proportions of essential workers and visible minorities (Table 1). Vaccinated individuals 253 were older; less likely to be male; more likely to have had multiple SARS-CoV-2 tests during the 254 3 months prior to the vaccination program; more likely to have a comorbidity; and more likely to 255 have received an influenza vaccine. Compared to recipients of mRNA-1273 vaccine, recipients 256 of BNT162b2 vaccine were younger, more likely to be female, and less likely to have a 257 258 comorbidity (eTable 4). The distribution of these vaccine products also differed by Public Health 259 Unit regions. Most individuals (77% for BNT162b2, 76% for mRNA-1273) had received only 1 dose by the index date. Distribution of vaccine product over the study period is presented in 260 eFigure 1. 261

262

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

	· · · · · · · · · · · · · · · · · · ·
263	Against symptomatic infection, adjusted VE $\geq$ 14 days after receiving only 1 dose was 60%
264	(95%CI, 57-64%). This increased from 48% (95%CI, 41-54%) at 14-20 days to a plateau of
265	71% (95%CI, 63–78%) at 35–41 days (Figure 2, eTable 5). We observed a 16% increase in risk
266	of symptomatic infection 7-13 days after a first dose (VE -16%; 95%CI, -26% to -6%), but no
267	increase 0-6 days after a first dose. VE $\geq$ 7 days after receiving 2 doses was 91% (95%CI, 89–
268	93%). Against severe outcomes of hospitalization or death, VE $\geq$ 14 days after receiving 1 dose
269	was 70% (95%CI, 60-77%), increasing from 62% (95%CI, 44-75%) at 14-20 days to 91%
270	(95%CI, 73–97%) at $\geq$ 35 days, whereas VE $\geq$ 7 days after receiving 2 doses was 98% (95%CI,
271	88–100%) ( <b>Figure 3, eTable 5</b> ).
272	
273	In subgroup analyses of VE against symptomatic infection, we observed higher VE $\geq$ 14 days
274	after receiving only 1 dose with mRNA-1273 than BNT162b2 (which was consistent across all
275	age groups), for younger adults than adults aged $\geq$ 70 years, for individuals with no comorbidities
276	than for those with comorbidities, and against the earlier variant and Alpha than Beta or Gamma
277	(though 95% confidence intervals for VE for variants overlapped) (Figure 4a, eTable 6).
278	However, VE estimates $\geq$ 7 days after receiving 2 doses were high (all $\geq$ 88%) and comparable
279	across all subgroups, including against E484K-positive variants. Against severe outcomes, we
280	observed higher VE $\geq$ 14 days after receiving 1 dose for younger adults aged 16-39 years, but VE
281	estimates after receiving 2 doses were mostly similar across subgroups (Figure 4b, eTable 7).
282	
283	Among adults ≥70 years, VE against symptomatic infection after 1 dose was 64% (95%CI 46–
284	76%) at 28–34 days and 85% (95%CI 38–97%) at 42–48 days, whereas comparable VE $$
285	estimates were achieved sooner after 1 dose for younger adults (Figure 5, eTable 8).

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

- Furthermore, VE against severe outcomes was similar at  $\geq$ 35 days after 1 dose (93%; 95% CI,
- 287 71–98%) as after receiving 2 doses (97%; 95%CI, 86–99%).
- 288
- Lastly, in the sensitivity analysis that restricted the analysis to vaccinated individuals and treated
- those vaccinated 0-13 days prior to the index date as the reference group, VE estimates against
- symptomatic infection were similar to the main analyses (eTable 5). However, for severe

292 outcomes, the estimates differed for earlier vaccination intervals.

293

#### 294 **DISCUSSION**

- 295 Using the test-negative design, which mitigates selection bias due to differences in health-
- seeking behaviour between vaccinated and unvaccinated individuals, we estimated very high
- 297 (>90%) vaccine effectiveness of mRNA vaccines BNT162b2 and mRNA-1273 against
- symptomatic SARS-CoV-2 infection with full vaccination (i.e.,  $\geq$ 7 days after receipt of a second
- dose), and moderate ( $\sim$ 50-70%) VE with partial vaccination (i.e.,  $\geq$ 14 days after receipt of only a
- 300 first dose). Estimates for both full and partial vaccination were approximately 10 percentage
- 301 points higher against hospitalization or death than symptomatic infection. VE generally increased
- 302 over time after a first dose, however we also noted a slightly increased risk of symptomatic
- infection on days 7-13 after a first dose, compared to no vaccination. In subgroup analyses, we
- observed lower VE against symptomatic infection in adults aged  $\geq$ 70 years and individuals with
- 305 comorbidities, but a higher VE after the first dose for mRNA-1273 recipients than BNT162b2
- recipients. However, VE was consistently high across subgroups for fully vaccinated individuals,
- and also for older adults after longer intervals following receipt of a first dose.
- 308

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

309	Our findings for fully vaccinated individuals are comparable with clinical trial efficacy estimates
310	and other real-world effectiveness estimates reported in a range of settings.[16,18-31] Existing
311	evidence estimating one-dose effectiveness of mRNA vaccines from observational studies is
312	heterogeneous,[16,27,30–32] with estimates for symptomatic infection ranging from 57%
313	(95%CI, 50–63%)[16] to 72% (95%CI, 58–86%)[31] and post-hoc calculations from efficacy
314	trials approximately 90%.[33,34] There is similar heterogeneity among one-dose effectiveness
315	estimates in older adults, [25, 32, 35] with estimates generally lower for older adults after the first
316	dose,[16,32] and increasing with time. Our analysis identified an effectiveness against
317	symptomatic infection of 63% (95%CI, 40–72%) ≥49 days after only the first dose, in keeping
318	with several other studies reporting one-dose effectiveness.[16,30] In addition, we found that one
319	dose of the mRNA-1273 vaccine had a significantly higher VE against symptomatic infection
320	than BNT162b2. Differences in characteristics between BNT162b2 and mRNA-1273 recipients
321	might explain this finding, but similar results were also found in another Canadian province.[36]
322	However findings were inconsistent in other studies that compared the effectiveness between
323	products after one dose; some found a trend towards higher VE against infection in mRNA-1273
324	recipients,[37,38] whereas others found no difference.[39,40] However for each, their study
325	populations were more homogeneous than ours (e.g., adults aged $\leq 40$ years, healthcare workers,
326	veterans). Our analysis also reflects extant evidence that effectiveness increases to very high
327	levels after the second dose, even in older adults against symptomatic infection[16] and COVID-
328	19-associated hospitalizations.[19,23] Lastly, our finding that receipt of 2 doses of mRNA
329	vaccines was not associated with appreciable vaccine escape by lineage Alpha or E484K-positive
330	variants (i.e., Beta and Gamma) is notable.

331

### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

332	In our study, we found an increased risk of infection 7-13 days after receiving the vaccine. An
333	increased risk of SARS-CoV-2 infection up to 14 days after the first dose was also found in other
334	studies.[25,31,41,42] This could be due to an increase in SARS-CoV-2 exposures after
335	vaccination. Individuals may assume protection immediately following vaccination and engage
336	in higher risk behaviours before a sufficient immune response has developed. Indeed,
337	approximately 20% of the US public believe that protection is conferred either immediately or 1-
338	2 weeks after the first dose.[43] Future studies should examine the potential role of behavioural
339	changes post first dose of COVID-19 vaccines. This finding could also be due a higher baseline
340	risk of infection among those who were initially prioritized to receive the vaccine, which may
341	not have been adequately controlled for in our models. However, a VE estimate of close to 0% 0-
342	6 days after a first dose provides a level of validation that differences between vaccinated and
343	unvaccinated individuals were accounted for.

344

Our study had some limitations. First, our study sample was limited to those with COVID-19 345 symptoms recorded in OLIS, which decreased our potential sample size considerably, from 346 2,171,449 individuals who were tested for SARS-CoV-2 to 324,033 individuals who had 347 relevant COVID-19 symptoms recorded in OLIS. Not all laboratories in Ontario currently have 348 the information technology infrastructure to submit symptom information (or documentation of 349 350 asymptomatic testing) recorded on the SARS-CoV-2 laboratory requisition into OLIS. Thus, the 351 generalizability of our findings to the broader population is uncertain and we could not evaluate VE against asymptomatic infection. However, the percent positivity of our study sample 352 353 (53,270/324,033=16.4%) was not dramatically different from the percent positivity observed in 354 Ontario during the study period (281,261/2,171,449=13.0%), and we would expect positivity to

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

355	be higher for symptomatic individuals than asymptomatic individuals. We also acknowledge that
356	those who had no symptom information recorded in OLIS may have been symptomatic at the
357	time of testing and those recorded as asymptomatic may have subsequently become
358	symptomatic. In addition, COVID-19 vaccination status may also be collected on the laboratory
359	requisition. This may bias the true VE estimate, depending on whether symptoms were more
360	likely to be documented on requisition forms for vaccinated individuals who ultimately test
361	positive for SARS-CoV-2 (bias VE towards the null) or have symptoms less likely recorded (bias
362	VE away from the null). Traditional test-negative design studies collect vaccination status among
363	all individuals with symptoms consistent with the pathogen under study to minimize this
364	selection bias. However, the congruence of our findings for fully vaccinated individuals with
365	extant studies provides some reassurance that any under- or overestimation of VE is likely to be
366	small. Second, because symptom onset date is largely unavailable in OLIS and CCM only has
367	information on test-positive cases, we used specimen collection date as the index date. This may
368	have led to classifying some vaccinated individuals into an incorrect dose-to-index date interval
369	because their symptom onset would have been several days prior to getting tested. The impact to
370	VE estimates for earlier intervals if using the specimen collection date depends on the test results
371	for vaccinated individuals (e.g., VE for earlier intervals would be overestimated if there were
372	more vaccinated test-positive cases and underestimated if there were more vaccinated test-
373	negative controls) or whether the lag between symptom onset and specimen collection dates
374	resulted in misclassification of vaccinated individuals (i.e., false negatives), which would
375	overestimate VE for earlier intervals. Furthermore, we could not limit the study population to
376	individuals tested within 10 days of symptom onset, a commonly used inclusion criterion for
377	test-negative studies. Prolonging the interval between symptom onset and testing increases the

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

378	likelihood of false-negative cases, which lowers VE estimates. However, 89% of cases with both
379	symptom onset and specimen collection date documented in CCM (not the source of symptom
380	data for this study) were tested within 10 days of symptom onset. Third, our results may have
381	been impacted by outcome misclassification of severe outcomes due to unlinked case records
382	and incomplete capture of severe outcomes in CCM, and delays in identifying hospitalizations in
383	DAD (which are dependent on individuals being discharged) and deaths in RPDB. The direction
384	of bias to VE estimates depends on whether data completeness and lags are differential between
385	vaccinated and unvaccinated test-positive cases (e.g., if vaccination status ascertained during the
386	case management process influenced the degree of data collection [e.g., if more complete among
387	vaccinated cases, VE would be biased towards the null], or if unvaccinated cases have a
388	prolonged hospitalization because of more severe course of illness, their hospitalization record
389	would not be available for analysis and VE would be biased towards the null). Fourth, some of
390	our covariates may be subject to measurement error. We used frequency of previous SARS-CoV-
391	2 tests as a proxy to identify individuals at higher risk of exposure (and increased likelihood to
392	be targeted for early vaccination). However, we did not include point-of-care tests because they
393	are incompletely captured in OLIS. Furthermore, since access to testing is variable, we might not
394	have adequately controlled for this concept. Finally, we may not have adequately accounted for
395	confounding bias with the covariates that were available in the study databases, especially
396	against severe outcomes.

397

Our findings suggest that older individuals and those with comorbidities may benefit from riskbased recommendations to minimize second-dose delays. However, rising protection against
severe outcomes – arguably the more important outcome – with increasing time after a first dose

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

401	provides support for delaying the second dose in settings that face vaccine supply constraints.
402	Mathematical modelling could be conducted to demonstrate how, particularly for jurisdictions
403	with limited vaccine supply, vaccines should be distributed to maximize population protection
404	(e.g., the relative benefits of providing second doses earlier to older populations versus providing
405	more first doses to younger populations who respond better to a single dose and leading to more
406	rapid achievement of herd immunity by maximizing coverage with 1 dose). Since VE against
407	symptomatic infection after 1 dose is only moderate, and among older adults appears to be
408	modest even at 14-20 days, individuals need to be informed that besides the absence of benefit
409	during the first 2 weeks (and likely longer for older adults) after a first dose, they should
410	continue to adhere to recommended public health measures, such as mask-wearing, physical

411 distancing, and avoidance of social gatherings.

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

#### 412 <u>Conflicts of interest</u>

- 413 KW is CEO of CANImmunize and serves on the data safety board for the Medicago COVID-19
- 414 vaccine trial. SMM has received unrestricted research grants from Merck, GlaxoSmithKline,
- 415 Sanofi Pasteur, Pfizer, and Roche-Assurex for unrelated studies. SMM has received fees as an
- 416 advisory board member for GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, and Seqirus. CHR
- 417 has received an unrestricted research grant from Pfizer for an unrelated study. The other authors
- 418 declare no conflicts of interest.
- 419

#### 420 <u>Contributors</u>

421 HC and JCK designed and oversaw the study. SH and HC obtained the data and conducted all

422 analyses (data set and variable creation and statistical modelling). BC contributed to data

- 423 analyses and data preparation for the symptomatic data set. SN, MES, HC, and JCK drafted the
- 424 manuscript. All authors contributed to the analysis plan, interpreted the results, critically
- reviewed and edited the manuscript, approved the final version, and agreed to be accountable for
- all aspects of the work.

427

#### 428 <u>Ethics approval</u>

429 ICES is a prescribed entity under Ontario's Personal Health Information Protection Act

430 (PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without

- 431 consent, for the purpose of analysis or compiling statistical information with respect to the
- 432 management of, evaluation or monitoring of, the allocation of resources to or planning for all or
- 433 part of the health system. Projects that use data collected by ICES under section 45 of PHIPA,

#### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

434	and use no other data, are exempt from REB review. The use of the data in this project is
435	authorized under section 45 and approved by ICES' Privacy and Legal Office.
436	
437	Funding
438	This work was supported by the Canadian Immunization Research Network (CIRN) through a
439	grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research
440	(CNF 151944). This project was also supported by funding from the Public Health Agency of
441	Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task
442	Force. This study was also supported by ICES, which is funded by an annual grant from the
443	Ontario Ministry of Health (MOH). JCK is supported by Clinician-Scientist Award from the
444	University of Toronto Department of Family and Community Medicine. PCA is supported by a
445	Mid-Career Investigator Award from the Heart and Stroke Foundation. Study sponsors had no
446	role in study design, interpretation of the findings, manuscript preparation, or the decision to
447	publish.
448	

449 Data availability statement

The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding

### CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

- 456 templates or macros that are unique to ICES and are therefore either inaccessible or may require
- 457 modification.
- 458
- 459 Dissemination statement
- 460 As this research involves information drawn from the entire population of Ontario, it is not
- 461 feasible to report these results to each individual Ontarian. However, the results from this
- 462 manuscript will be made publicly available through a pre-print server and through dissemination
- 463 by ICES, news media, and other means.
- 464
- 465 <u>Transparency declaration</u>
- 466 JCK affirms that the manuscript is an honest, accurate, and transparent account of the study
- 467 being reported; that no important aspects of the study have been omitted; and that any
- discrepancies from the study as planned have been explained.
- 469
- 470 <u>Acknowledgments</u>
- 471 We would like to acknowledge Public Health Ontario for access to case-level data from CCM
- and COVID-19 laboratory data, as well as assistance with data interpretation. We also thank the
- staff of Ontario's public health units who are responsible for COVID-19 case and contact
- 474 management and data collection within CCM. We thank IQVIA Solutions Canada Inc. for use of
- their Drug Information Database. The authors are grateful to the Ontario residents without whom
- this research would be impossible.
- 477
- 478 <u>Disclaimers</u>

## CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

479	This study was supported by ICES, which is funded by an annual grant from the Ontario
480	Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This study was
481	supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to
482	support Ontario's ongoing response to COVID-19 and its related impacts. The study sponsors
483	did not participate in the design and conduct of the study; collection, management, analysis and
484	interpretation of the data; preparation, review or approval of the manuscript; or the decision to
485	submit the manuscript for publication. Parts of this material are based on data and/or information
486	compiled and provided by the Canadian Institute for Health Information (CIHI) and by Cancer
487	Care Ontario (CCO). However, the analyses, conclusions, opinions and statement expressed
488	herein are solely those of the authors, and do not reflect those of the funding or data sources; no
489	endorsement by ICES, MOH, MLTC, OHDP, its partners, the Province of Ontario, CIHI or CCO
490	is intended or should be inferred.
491	
492	Licence for Publication
493	The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf
494	of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide
495	basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published
496	in BMJ and any other BMJPGL products and sublicences such use and exploit all subsidiary

497 rights, as set out in our licence (<u>http://group.bmj.com/products/journals/instructions-for-</u>
498 <u>authors/licence-forms</u>).

# CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

# 500 **References**

501	1	Patel M, Jackson M, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines.							
502	-	<i>JAMA</i> 2020; <b>324</b> :1939–40. doi:10.1001/JAMA.2020.19328							
503	2	National Advisory Committee on Immunization. COVID-19 vaccine: Guidance on the							
504		prioritization of initial doses - Canada.ca. 2021.https://www.canada.ca/en/public-							
505		health/services/immunization/national-advisory-committee-on-immunization-							
506		naci/guidance-prioritization-initial-doses-covid-19-vaccines.html (accessed 2 May 2021).							
507	3	Jackson M, Nelson J. The test-negative design for estimating influenza vaccine							
508		effectiveness. Vaccine 2013; <b>31</b> :2165–8. doi:10.1016/J.VACCINE.2013.02.053							
509	4	Sullivan S, Tchetgen Tchetgen E, Cowling B. Theoretical Basis of the Test-Negative							
510		Study Design for Assessment of Influenza Vaccine Effectiveness. Am J Epidemiol							
511		2016; <b>184</b> :345–53. doi:10.1093/AJE/KWW064							
512	5	Watson J, Whiting P, Brush J. Interpreting a covid-19 test result. BMJ 2020;369.							
513		doi:10.1136/BMJ.M1808							
514	6	Updates to PHO's Variants of Concern Laboratory Testing   Public Health Ontario.							
515		2021.https://www.publichealthontario.ca/en/about/blog/2021/lab-voc-testing-updates							
516		(accessed 3 May 2021).							
517	7	Ontario's COVID-19 vaccination plan   COVID-19 (coronavirus) in Ontario.							
518		2021.https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan#our-three-phased-							
519		vaccination-plan (accessed 3 May 2021).							
520	8	Vaccine Clinical Advisory Group (VCAG) Recommendations on Exceptions to Extended							
521		Dose Intervals for COVID-19 vaccines. Ontario Ministry of Health 2021.							
522		https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/CO							
523		VID_19_medical_exceptions_vaccine_dose_intervals.pdf (accessed 3 May 2021).							
524	9	Extension of the Second Dose. Ontario Ministry of Health 2021.							
525		https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/CO							
526		VID_19_vaccine_dose_intervals.pdf (accessed 3 May 2021).							
527	10	ICES COVID-19 Dashboard. 2021.https://www.ices.on.ca/DAS/AHRQ/COVID-19-							
528		Dashboard (accessed 3 May 2021).							
529	11	Underlying medical conditions associated with high risk for severe COVID-19:							
530		Information for healthcare providers. 2021.https://www.cdc.gov/coronavirus/2019-							
531		ncov/hcp/clinical-care/underlyingconditions.html (accessed 3 May 2021).							
532	12	Kwong JC, Buchan SA, Chung H, et al. Can routinely collected laboratory and health							
533		administrative data be used to assess influenza vaccine effectiveness? Assessing the							
534		validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort. Vaccine							
535		2019; <b>37</b> :4392–400.							
536	13	Dictionary, Census of Population, 2016 - Dissemination area (DA). Statistics							
537		Canada/Statistique Canada 2016. https://www12.statcan.gc.ca/census-							
538		recensement/2016/ref/dict/geo021-eng.cfm (accessed 24 Jul 2021).							
539	14	Sundaram M, Calzavara A, Mishra S, et al. Individual and social determinants of SARS-							
540		CoV-2 testing and positivity in Ontario, Canada: a population-wide study. CMAJ							
541		2021; <b>193</b> :E723–34. doi:10.1503/CMAJ.202608							
542	15	Evaluation of COVID-19 vaccine effectiveness. 2021.							
543		https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine effectiveness-							
544		measurement-2021.1 (accessed 24 Jul 2021).							

# CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

- 545 16 Dagan N, Barda N, Kepten E, *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide
  546 Mass Vaccination Setting. *N Engl J Med* 2021;**384**:1412–23.
  547 doi:10.1056/NEJMOA2101765
  548 17 Hitchings MDT, Lewnard JA, Dean NE, *et al.* Use of recently vaccinated individuals to
- detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness.
   *medRxiv* 2021.
- Mason T, Whitston M, Hodgson J, *et al.* Effects of BNT162b2 mRNA vaccine on Covidinfection and hospitalisation among older people: matched case control study for
  England. *medRxiv* 2021.
- Haas E, Angulo F, McLaughlin J, *et al.* Impact and effectiveness of mRNA BNT162b2
  vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and
  deaths following a nationwide vaccination campaign in Israel: an observational study
  using national surveillance data. *Lancet* 2021;**397**:1819–29. doi:10.1016/S01406736(21)00947-8
- Thompson M, Burgess J, Naleway A, *et al.* Interim Estimates of Vaccine Effectiveness of
  BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection
  Among Health Care Personnel, First Responders, and Other Essential and Frontline
  Workers Eight U.S. Locations, December 2020–March. *MMWR Morb Mortal Wkly Rep* 2021;**70**:495–500. doi:10.15585/MMWR.MM7013E3
- Angel Y, Spitzer A, Henig O, *et al.* Association Between Vaccination With BNT162b2
  and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health
  Care Workers. *JAMA* 2021;**325**:2457–65. doi:10.1001/JAMA.2021.7152
- Tang L, Hijano DR, Gaur AH, *et al.* Asymptomatic and Symptomatic SARS-CoV-2
  Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. *JAMA*2021;**325**:2500–2. doi:10.1001/JAMA.2021.6564
- Tenforde M, Olson S, Self W, *et al.* Effectiveness of Pfizer-BioNTech and Moderna
  Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years United
  States, January–March 2021, *MMWR Morb Mortal Wkly Rep* 2021;**70**:674–9.
  doi:10.15585/MMWR.MM7018E1
- Björk J, Inghammar M, Moghaddassi M, *et al.* Effectiveness of the BNT162b2 vaccine in
  preventing COVID-19 in the working age population first results from a cohort study in
  Southern Sweden. *medRxiv* 2021.
- Lopez-Bernal J, Andrews N, Gower C, *et al.* Effectiveness of the Pfizer-BioNTech and
  Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and
  mortality in older adults in England: test negative case-control study. *BMJ* 2021;**373**.
  doi:10.1136/BMJ.N1088
- 26 Pawlowski C, Lenehan P, Puranik A, *et al.* FDA-authorized mRNA COVID-19 vaccines
  are effective per real-world evidence synthesized across a multi-state health system. *Med*(*New York, NY*) Published Online First: 2021. doi:10.1016/J.MEDJ.2021.06.007
- Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated
   counts. *medRxiv* 2021.
- Yelin I, Katz R, Herzel E, *et al.* Associations of the BNT162b2 COVID-19 vaccine
  effectiveness with patient age and comorbidities. *medRxiv* 2021.
- Vasileiou E, Simpson C, Shi T, *et al.* Interim findings from first-dose mass COVID-19
  vaccination roll-out and COVID-19 hospital admissions in Scotland: a national
- 590 prospective cohort study. *Lancet* 2021;**397**:1646–57. doi:10.1016/S0140-6736(21)00677-2

# CONFIDENTIAL – NOT FOR DISTRIBUTION 24 JUL 2021

30 Andrejko KL, Pry J, Myers JF, et al. Prevention of COVID-19 by mRNA-based vaccines 591 within the general population of California. medRxiv 2021. 592 Hall V, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in 31 593 594 England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021;397:1725–35. doi:10.1016/S0140-595 596 6736(21)00790-X Chodick G, Tene L, Patalon T, et al. The effectiveness of the first dose of BNT162b2 597 32 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world 598 evidence. medRxiv 2021;:2021.01.27.21250612. doi:10.1101/2021.01.27.21250612 599 33 Skowronski D, De Serres G. Safety and Efficacy of the BNT162b2 mRNA Covid-19 600 601 Vaccine: Letter to the Editor. N Engl J Med 2021;384:1576-8. doi:10.1056/NEJMC2036242 602 Annex A: Report to JCVI on estimated efficacy of a single dose of Pfizer BioNTech 34 603 (BNT162b2 mRNA) vaccine and of a single dose of ChAdOx1 vaccine (AZD1222). Public 604 605 Health England 2020. 35 Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-606 607 19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis Published Online First: 2021. 608 doi:10.1016/S1473-3099(21)00330-3 609 COVID-19 Alberta statistics | alberta.ca. https://www.alberta.ca/stats/covid-19-alberta-610 36 statistics.htm#vaccine-outcomes (accessed 24 Jul 2021). 611 Swift M, Breeher L, Tande A, et al. Effectiveness of mRNA COVID-19 vaccines against 37 612 SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis Published 613 Online First: 26 April 2021. doi:10.1093/CID/CIAB361 614 COVID-19 vaccine surveillance report - week 26. Public Health England 2021. 615 38 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment d 616 ata/file/998411/Vaccine\_surveillance\_report\_-\_week\_26.pdf (accessed 24 Jul 2021). 617 39 Butt A, Omer S, Yan P. et al. SARS-CoV-2 Vaccine Effectiveness in a High-Risk 618 National Population in a Real-World Setting. Ann Intern Med Published Online First: 619 2021. doi:10.7326/M21-1577 620 40 Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 621 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med 2021;385:320-9. 622 623 doi:10.1056/NEJMOA2107058 41 Chemaitelly H, Yassine H, Benslimane F, et al. mRNA-1273 COVID-19 vaccine 624 effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in 625 Oatar. Nat Med Published Online First: 2021. doi:10.1038/S41591-021-01446-Y 626 627 42 Hunter PR, Brainard J. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes 628 629 from Israel. medRxiv 2021. 43 Goldfarb JL, Kreps S, Brownstein JS, et al. Beyond the First Dose — Covid-19 Vaccine 630 Follow-through and Continued Protective Measures. N Engl J Med Published Online First: 631 632 2021. doi:10.1056/NEJMP2104527 633

Characteristic	SARS-CoV-2- positive, n (%) <sup>a</sup> (N=53,270)	SARS-CoV-2- negative, n (%) <sup>a</sup> (N=270,763)	Standardized difference <sup>b</sup>	Vaccinated with ≥1 dose of mRNA COVID-19 vaccine, n (%) <sup>a</sup> (N=21 272)	Unvaccinated, n (%) <sup>a</sup> (N=302,761)	Standardized difference <sup>b</sup>
Received $\geq 1$ dose of COVID-19 vaccine	2.050 (3.8)	19.222 (7.1)	_	-	-	_
Received 2 doses of COVID-19 vaccine	73 (0.1)	4.821 (1.8)	-	-	-	-
Tested positive for SARS-CoV-2	-	-	-	2.050 (9.6)	51,220 (16,9)	-
Earlier variant	-	-	-	579 (2.7)	27.510 (9.1)	-
Alpha (B.1.1.7)	-	-	-	807 (3.8)	12,282 (4.1)	-
Beta (B.1.351) or Gamma (P.1)	-	-	-	98 (0.5)	1,291 (0.4)	-
(E484K+ variants)					, , ,	
Age (years), mean (standard deviation)	42.4 (17.1)	43.2 (17.8)	0.04	51.8 (20.8)	42.4 (17.3)	0.49
Age group (years)						
16–29	15,175 (28.5)	72,238 (26.7)	0.04	3,457 (16.3)	83,956 (27.7)	0.28
30–39	10,024 (18.8)	59,326 (21.9)	DO NO 0,08 JTE	4,011 (18.9)	65,339 (21.6)	0.07
40–49	9,642 (18.1)	46,225 (17.1)	0.03	3,287 (15.5)	52,580 (17.4)	0.05
50–59	9,460 (17.8)	40,874 (15.1)	0.07	3,112 (14.6)	47,222 (15.6)	0.03
60–69	5,279 (9.9)	27,342 (10.1)	0.01	2,261 (10.6)	30,360 (10.0)	0.02
70–79	2,426 (4.6)	14,888 (5.5)	0.04	2,272 (10.7)	15,042 (5.0)	0.21
≥80	1,264 (2.4)	9,870 (3.6)	0.07	2,872 (13.5)	8,262 (2.7)	0.40
Male sex	25,993 (48.8)	112,501 (41.5)	0.15	6,013 (28.3)	132,481 (43.8)	0.33
Public health unit region <sup>c</sup>						
Central East	2,624 (4.9)	29,194 (10.8)	0.22	1,969 (9.3)	29,849 (9.9)	0.02
Central West	8,322 (15.6)	48,419 (17.9)	0.06	3,853 (18.1)	52,888 (17.5)	0.02
Durham	1,433 (2.7)	8,583 (3.2)	0.03	522 (2.5)	9,494 (3.1)	0.04
Eastern	689 (1.3)	15,147 (5.6)	0.24	1,087 (5.1)	14,749 (4.9)	0.01
North	1,753 (3.3)	31,321 (11.6)	0.32	2,251 (10.6)	30,823 (10.2)	0.01
Ottawa	417 (0.8)	3,144 (1.2)	0.04	446 (2.1)	3,115 (1.0)	0.09
Peel	13,515 (25.4)	32,981 (12.2)	0.34	2,395 (11.3)	44,101 (14.6)	0.10
South West	7,562 (14.2)	39,316 (14.5)	0.01	3,885 (18.3)	42,993 (14.2)	0.11
Toronto	12,458 (23.4)	45,540 (16.8)	0.16	3,462 (16.3)	54,536 (18.0)	0.05
York	4,278 (8.0)	15,995 (5.9)	0.08	1,323 (6.2)	18,950 (6.3)	0.00
Biweekly period of test						
14 Dec 2020 to 27 Dec 2020	4,139 (7.8)	27,456 (10.1)	0.08	13 (0.1)	31,582 (10.4)	0.48

Table 1. Characteristics of symptomatic individuals tested for SARS-CoV-2 between 14 December 2020 and 19 April 2021 in Ontario, Canada.

Characteristic	SARS-CoV-2-	SARS-CoV-2-	Standardized	Vaccinated with ≥1	Unvaccinated,	Standardized
	positive,	negative,	difference <sup>®</sup>	dose of mRNA	n (%) <sup>a</sup> (N-302 761)	difference <sup>b</sup>
	(N=53.270)	(N=270.763)		$n (\%)^a$	(11-302,701)	
	(1, 00, 1, 0)	(1 ( 1 ( ) ( ) ( ) ( ) )		(N=21,272)		
28 Dec 2020 to 10 Jan 2021	6,870 (12.9)	26,993 (10.0)	0.09	335 (1.6)	33,528 (11.1)	0.40
11 Jan 2021 to 24 Jan 2021	4,864 (9.1)	26,747 (9.9)	0.03	1,068 (5.0)	30,543 (10.1)	0.19
25 Jan 2021 to 7 Feb 2021	3,539 (6.6)	24,276 (9.0)	0.09	1,204 (5.7)	26,611 (8.8)	0.12
8 Feb 2021 to 21 Feb 2021	3,595 (6.7)	24,800 (9.2)	0.09	1,031 (4.8)	27,364 (9.0)	0.17
22 Feb 2021 to 7 Mar 2021	3,539 (6.6)	30,760 (11.4)	0.17	1,491 (7.0)	32,808 (10.8)	0.13
8 Mar 2021 to 21 Mar 2021	5,134 (9.6)	32,776 (12.1)	0.08	2,790 (13.1)	35,120 (11.6)	0.05
22 Mar 2021 to 4 Apr 2021	8,338 (15.7)	35,910 (13.3)	0.07	4,814 (22.6)	39,434 (13.0)	0.25
5 Apr 2021 to 19 Apr 2021	13,252 (24.9)	41,045 (15.2)	0.24	8,526 (40.1)	45,771 (15.1)	0.58
Number of tests in previous 3 months						
0	43,713 (82.1)	189,786 (70.1)	0.28	11,588 (54.5)	221,911 (73.3)	0.40
1	7,151 (13.4)	54,827 (20.2)	0.18	4,338 (20.4)	57,640 (19.0)	0.03
≥2	2,406 (4.5)	26,150 (9.7)	0.20	5,346 (25.1)	23,210 (7.7)	0.49
Any comorbidity <sup>d</sup>	23,212 (43.6)	127,974 (47.3)	0.07 JTE	12,218 (57.4)	138,968 (45.9)	0.23
Receipt of 2019-2020 and/or 2020-2021	13,751 (25.8)	89,395 (33.0)	0.16	9,587 (45.1)	93,559 (30.9)	0.30
influenza vaccination						
Household income quintile <sup>c, e</sup>						
1 (lowest)	11,878 (22.3)	47,944 (17.7)	0.11	3,750 (17.6)	56,072 (18.5)	0.02
2	11,154 (20.9)	51,470 (19.0)	0.05	4,146 (19.5)	58,478 (19.3)	0.00
3	11,477 (21.5)	52,628 (19.4)	0.05	4,233 (19.9)	59,872 (19.8)	0.00
4	10,146 (19.0)	56,676 (20.9)	0.05	4,513 (21.2)	62,309 (20.6)	0.02
5 (highest)	8,359 (15.7)	60,774 (22.4)	0.17	4,540 (21.3)	64,593 (21.3)	0.00
Essential workers quintile <sup>c, f</sup>						
1 (0%-32.5%)	6,440 (12.1)	50,664 (18.7)	0.18	3,917 (18.4)	53,187 (17.6)	0.02
2 (32.5%-42.3%)	11,225 (21.1)	60,040 (22.2)	0.03	4,664 (21.9)	66,601 (22.0)	0.00
3 (42.3%-49.8%)	11,106 (20.8)	56,108 (20.7)	0.00	4,468 (21.0)	62,746 (20.7)	0.01
4 (50.0%-57.5%)	11,576 (21.7)	52,849 (19.5)	0.05	4,211 (19.8)	60,214 (19.9)	0.00
5 (57.5%-100%)	12,519 (23.5)	49,067 (18.1)	0.13	3,859 (18.1)	57,727 (19.1)	0.02
Persons per dwelling quintile <sup>c, g</sup>						
1 (0–2.1)	5,781 (10.9)	51,852 (19.2)	0.23	4,277 (20.1)	53,356 (17.6)	0.06
2 (2.2–2.4)	6,641 (12.5)	52,326 (19.3)	0.19	4,219 (19.8)	54,748 (18.1)	0.04
3 (2.5–2.6)	5,633 (10.6)	37,229 (13.7)	0.10	3,020 (14.2)	39,842 (13.2)	0.03

Characteristic	SARS-CoV-2- positive, n (%) <sup>a</sup> (N=53,270)	SARS-CoV-2- negative, n (%) <sup>a</sup> (N=270,763)	Standardized difference <sup>b</sup>	Vaccinated with ≥1 dose of mRNA COVID-19 vaccine, n (%) <sup>a</sup> (N=21,272)	Unvaccinated, n (%) <sup>a</sup> (N=302,761)	Standardized difference <sup>b</sup>
4 (2.7–3.0)	12,967 (24.3)	63,774 (23.6)	0.02	4,874 (22.9)	71,867 (23.7)	0.02
5 (3.1–5.7)	21,833 (41.0)	63,459 (23.4)	0.38	4,709 (22.1)	80,583 (26.6)	0.10
Self-identified visible minority quintile <sup>c, h</sup>						
1 (0.0%-2.2%)	4,437 (8.3)	51,919 (19.2)	0.32	4,133 (19.4)	52,223 (17.2)	0.06
2 (2.2%-7.5%)	5,752 (10.8)	55,124 (20.4)	0.27	4,592 (21.6)	56,284 (18.6)	0.07
3 (7.5%–18.7%)	7,223 (13.6)	51,122 (18.9)	0.14	3,982 (18.7)	54,363 (18.0)	0.02
4 (18.7%–43.5%)	10,718 (20.1)	53,691 (19.8)	0.01	3,974 (18.7)	60,435 (20.0)	0.03
5 (43.5%-100%)	24,736 (46.4)	56,876 (21.0)	0.56	4,438 (20.9)	77,174 (25.5)	0.11

<sup>a</sup>Proportion reported, unless stated otherwise.

<sup>b</sup>Standardized differences of >0.10 are considered clinically relevant.

"The sum of counts does not equal the column total because of individuals with missing information (<1.0%) for this characteristic.

<sup>d</sup>Comorbidities include chronic respiratory diseases, chronic heart diseases, hypertension, diabetes, immunocompromising conditions due to underlying diseases or therapy, autoimmune diseases, chronic kidney disease, advanced liver disease, dementia/frailty and history of stroke or transient ischemic attack.

<sup>e</sup>Household income quintile has variable cut-off values in each city/Census area to account for cost of living. A dissemination area (DA) being in quintile 1 means it is among the lowest 20% of DAs in its city by income. <sup>f</sup>Percentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture, and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision. <sup>g</sup>Range of persons per dwelling.

<sup>h</sup>Percentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

**Figure 1:** Community-dwelling adults included in the tested cohort between 14 December 2020 and 19 April 2021 in Ontario, Canada.



<sup>&</sup>lt;sup>a</sup>Recorded symptoms not consistent with COVID-19 (e.g., anxiety, cancer, falls)



**Figure 2.** Unadjusted (panel A) and adjusted<sup>†</sup> (panel B) vaccine effectiveness estimates of COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) against laboratory-confirmed symptomatic SARS-CoV-2 infection by various intervals, between 14 December 2020 and 19 April 2021 in Ontario, Canada.

<sup>&</sup>lt;sup>†</sup> Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood-level household income, persons per dwelling, proportion of persons employed as non-health essential workers, and self-identified visible minority quintiles.

**Figure 3.** Unadjusted (panel A) and adjusted<sup>\*</sup> (panel B) vaccine effectiveness estimates of COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) against severe outcomes (hospitalization or death) associated with laboratory-confirmed symptomatic SARS-CoV-2 infection by various intervals, between 14 December 2020 and 19 April 2021 in Ontario, Canada.



<sup>\*</sup> Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood-level household income, persons per dwelling, proportion of persons employed as non-health essential workers, and self-identified visible minority quintiles.

# CONFIENTAL DISTURIE AL

**Figure 4.** Adjusted<sup>\*</sup> vaccine effectiveness estimates  $\geq 14$  days after Dose 1 (for individuals who received only 1 dose) and  $\geq 0$  days after Dose 2 by various factors, including vaccine product, patient characteristics, epidemic wave, and SARS-CoV-2 lineage against laboratory-confirmed symptomatic SARS-CoV-2 infection (panel A) and severe outcomes (hospitalization or death) (panel B) between 14 December 2020 and 19 April 2021.



#### A) Against symptomatic infection B) Against severe outcomes

<sup>\*</sup> Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood-level household income, persons per dwelling, proportion of persons employed as non-health essential workers, and self-identified visible minority quintiles (unless adjusted variable was used for stratification).

<sup>\*\*</sup>For vaccine effectiveness against symptomatic SARS-CoV-2 infection (panel A), this interval was  $\geq$ 7 days after Dose 2. However, against serious outcomes (panel B), VE was evaluated for the entire period (i.e.,  $\geq$ 0 days) after receipt of the second dose due to the small number of outcomes.

<sup>&</sup>lt;sup>+</sup>For subgroup analyses by characteristic and SARS-CoV-2 lineage, individuals vaccinated with either mRNA vaccine was included.

**Figure 5.** Adjusted<sup>\*</sup> vaccine effectiveness estimates  $\geq 14$  days after Dose 1 and  $\geq 0$  days after Dose 2 in community-dwelling adults in Ontario, Canada against laboratory-confirmed symptomatic SARS-CoV-2 infection for adults aged  $\geq 70$  years (panel A), 40-69 years (panel B), and 16-39 years (panel C) and severe outcomes (hospitalization or death) for adults aged  $\geq 70$  years (panel D) and 40-69 years (panel E), between 14 December 2020 and 19 April 2021.



<sup>\*</sup> Models were adjusted for age, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood-level household income, persons per dwelling, proportion of persons employed as non-health essential workers, and self-identified visible minority quintiles (unless adjusted variable was used for stratification).

<sup>\*\*</sup>For vaccine effectiveness against symptomatic SARS-CoV-2 infection (panels A, B, and C), this interval was  $\geq$ 7 days after Dose 2. Against serious outcomes (panels D and E), vaccine effectiveness was evaluated for the entire period (i.e.,  $\geq$ 0 days) after receipt of the second dose due to the small number of outcomes.

# CONFIENTALDETSNEUTEIAL